login
register
Home
Getting Started
ChartMill Overview
Growth Traders
Technical Swing Traders
Long Term Investors
Tools
Stock Screener
Stock Charts
Full Screen Stock Charts
Market Monitor
Sectors
Earnings
Analyzer
Insider Trading
Up- and Downgrades
Stock Market
Top Gainers and Losers
New 52 Week High and Low
Gap Up and Gap Down
Most Active
Premarket Movers
After-Hours Movers
Earnings Calendar
USA Market Overview
Canada Market Overview
Europe Market Overview
Trading Ideas
News
Blog
Documentation
Documentation Center
Videos
Indicators
Properties
Screener Market data
Popular Articles
Bull Flags
Relative Strength
Pocket Pivots
Support and Resistance
RSI Indicator
MACD Indicator
Piotroski F-score
Squeeze Plays
Weinstein
Technical Breakout Setups
Trading Tips
Premarket Movers
Gap Up Stocks
Best Dividend Stocks
Bullish Engulfing Pattern
Ascending Triangle Pattern
Swing Trading
All articles ...
Subscriptions
Swing Trading Course
Account
Disclaimer
Affiliate
Contact
Privacy
MESOBLAST LTD- SPON ADR (MESO) Stock News
USA
- NASDAQ:MESO -
US5907174016
-
ADR
14.92
USD
-0.78 (-4.97%)
Last: 11/13/2025, 8:00:01 PM
14.85
USD
-0.07 (-0.47%)
After Hours:
11/13/2025, 8:00:01 PM
Overview
Stock Chart
Technical Analysis
Fundamental Analysis
Analyst Ratings
Earnings Estimates
Financials
Ownership
News
MESO Latest News, Press Relases and Analysis
All
Press Releases
4 days ago - By: Zacks Investment Research
Bears are Losing Control Over Mesoblast Limited (MESO), Here's Why It's a 'Buy' Now
9 days ago - By: Mesoblast Limited
Mesoblast to Meet With FDA Next Month to Discuss Rexlemestrocel-L and Opioid Cessation
16 days ago - By: Zacks Investment Research
All You Need to Know About Mesoblast Limited (MESO) Rating Upgrade to Buy
25 days ago - By: Mesoblast Limited
Ryoncil® Net Revenues Increase 69% in Second Quarter Post Launch
a month ago - By: Benzinga
- Mentions:
BITF
WULF
SLI
ALMU
...
Bitfarms, Standard Lithium, Terawulf And Other Big Stocks Moving Lower In Friday's Pre-Market Session
a month ago - By: Mesoblast Limited
Ryoncil® Revenues Increase 66% in Second Quarter Post Launch
3 months ago - By: Benzinga
Examining the Future: Mesoblast's Earnings Outlook
4 months ago - By: Mesoblast Limited
Successful Commercial Launch of Ryoncil®
a month ago - By: Mesoblast Limited
Ryoncil® Receives J-Code From Medicare & Medicaid Services (CMS) Facilitating Reimbursement and Broader Patient Access
2 months ago - By: Mesoblast Limited
Mesoblast Cell Therapy Products are Designated U.S. Origin and Not Subject to Tariffs
2 months ago - By: Mesoblast Limited
Successful Commercial Launch of Ryoncil® Highlighted at Global Healthcare Conferences
2 months ago - By: Mesoblast Limited
Mesoblast Enters Into Option To Issue US$50 Million Convertible Notes
3 months ago - By: Mesoblast Limited
Banner Year for Mesoblast With First FDA Product Approval and Successful Commercial Launch of Ryoncil®
3 months ago - By: Mesoblast Limited
Mesoblast Financial Results and Corporate Update Webcast
4 months ago - By: Yahoo Finance
Mesoblast Limited (MESO) Launches First Cell Therapy for Children
Please enable JavaScript to continue using this application.